Predictive factors of tumour response after neoadjuvant chemoradiation for locally advanced rectal cancer and correlation of these factors with survival;Facteurs prédictifs de réponse à la radiochimiothérapie néoaduvante dans les cancers rectaux localement évolués et corrélation de ces facteurs avec la survie

Cancer/Radiotherapie

Volumn 15, Issue 4, 2011, Pages 279-286

  Farnault, B ^a   Moureau Zabotto, L ^a   de Chaisemartin, C ^a   Esterni, B ^a   Lelong, B ^a   Viret, F ^a   Giovannini, M ^a   Monges, G ^a   Delpero, J R ^a   Bories, E ^a   Turrini, O ^a   Viens, P ^a   Resbeut, M ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Neoadjuvant chemoradiation; Predictive factors; Rectal cancer; Tumour response

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; ECHOGRAPHY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RECTUM CANCER; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 79960045416     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2011.01.005     Document Type: Article

References (29)

1. Heald R.J., Husband E.M., Ryall R.D. The mesorectum in rectal cancer surgery - the clue to pelvic recurrence?. Br J Surg 1982, 69:613-616.
2. Blanchard P., Lévy A., Breunot J., Michaud S., Delmas V., Hennequin C. Le cancer du rectum. Cancer Radiother 2010, 14:S111-S119.
3. Blanchard P., Chapet O. Dose de tolérance à l'irradiation des tissus sains: le rectum. Cancer Radiother 2010, 14:354-358.
4. Bosset J.F., Nguyen F., Bosset M., Servagi-Vernat S., Sedrati A., Lorgis V. Traitements préopératoires des cancers rectaux. Cancer Radiother 2007, 11:349-352.
5. Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis 2006, 8Suppl3:21-24.
6. Dhadda A.S., Zaitoun A.M., Bessell E.M. Regression of rectal cancer with radiotherapy with or without concurrent capecitabine - optimising the timing of surgical resection. Clin Oncol (R Coll Radiol) 2009, 21:23-31.
7. Benzoni E., Intersimone D., Terrosu G., Bresadola V., Cojutti A., Cerato F., et al. Prognostic value of tumour regression grading and depth of neoplastic infiltration within the perirectal fat after combined neoadjuvant chemo-radiotherapy and surgery for rectal cancer. J Clin Pathol 2006, 59:505-512.
8. Rödel C., Martus P., Papadoupolos T., Füzesi L., Klimpfinger M., Fietkau R., et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23:8688-8696.
9. Theodoropoulos G., Wise W.E., Padmanabhan A., Kerner B.A., Taylor C.W., Aguilar P.S., et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002, 45:895-903.
10. Das P., Skibber J.M., Rodriguez-Bigas M.A., Feig B.W., Chang G.J., Wolff R.A., et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007, 109:1750-1755.
11. Moreno García V., Cejas P., Blanco Codesido M., Feliu Batlle J., de Castro Carpeño J., Belda-Iniesta C., et al. Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Colorectal Dis 2009, 24:741-748.
12. Perez R.O., São Julião G.P., Habr-Gama A., Kiss D., Proscurshim I., Campos F.G., et al. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Dis Colon Rectum 2009, 52:1137-1143.
13. American Joint Committee on Cancer AJCC cancer staging manual 2002, Springer, New York, p. 157-64. 6th ed.
14. Quirke P., Durdey P., Dixon M.F., Williams N.S. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986, 2:996-999.
15. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
16. Janjan N.A., Crane C., Feig B.W., Cleary K., Dubrow R., Curley S., et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001, 24:107-112.
17. Garcia-Aguilar J., Pollack J., Lee S.H., Hernandez de Anda E., Mellgren A., Wong W.D., et al. Accuracy of endorectal ultrasonography in preoperative staging of rectal tumors. Dis Colon Rectum 2002, 45:10-15.
18. Crane C.H., Sargent D.J. Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need?. J Clin Oncol 2004, 22:2978-2981.
19. Dunst J., Debus J., Rudat V., Wulf J., Budach W., Hoelscher T., et al. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther Onkol 2008, 184:450-456.
20. Ortholan C., François É., Follana P., Gérard J.P. Place de l'oxaliplatine dans les chimioradiothérapies des cancers du rectum. Bull Cancer 2006, 93:S51-S58.
21. Debucquoy A., Haustermans K., Daemen A., Aydin S., Libbrecht L., Gevaert O., et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009, 27:2751-2757.
22. Zlobec I., Vuong T., Compton C.C., Lugli A., Michel R.P., Hayashi S., et al. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Br J Cancer 2008, 98:450-456.
23. Horisberger K., Treschl A., Mai S., Barreto-Miranda M., Kienle P., Ströbel P., et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys 2009, 74:1487-1493.
24. Willett C.G., Warland G., Coen J., Shellito P.C., Compton C.C. Rectal cancer: the influence of tumor proliferation on response to preoperative irradiation. Int J Radiat Oncol Biol Phys 1995, 32:57-60.
25. Berardi R, Mantello G, Scartozzi M, Del Prete S, Luppi G, Martinelli R, et al. Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome. Int J Radiat Oncol Biol Phys 2009;75:1437-43.
26. Zlobec I., Steele R., Nigam N., Compton C.C. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. Clin Cancer Res 2005, 11:5440-5443.
27. O'Neill B.D., Brown G., Heald R.J., Cunningham D., Tait D.M. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 2007, 8:625-633.
28. Gérard J.P., Conroy T., Bonnetain F., Bouché O., Chapet O., Closon-Dejardin M.T., et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24:4620-4625.
29. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., Michalski W., Bebenek M., Pudełko M., et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs conventionally fractionated radiochemotherapy. Radiother Oncol 2004, 72:15-24.